Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Endocrine-related cancer"
DOI: 10.1530/erc-19-0098
Abstract: Thyroid cancer is mostly an ERK-driven carcinoma, as up to 70% of thyroid carcinomas are caused by mutations that activate the RAS/ERK mitogenic signaling pathway. The incidence of thyroid cancer has been steadily increasing for… read more here.
Keywords: therapeutic targets; erk pathway; cancer; ras erk ... See more keywords